Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafasitamab - Incyte Corporation

Next Previous
Drug Profile

Tafasitamab - Incyte Corporation

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; ICP-B04; INCA-000585; INCMOR0208; MINJUVI; Minjuvi; Monjuvi; MOR 208; MOR-00208; Tafasitamab-cxix; XENP-5574; XmAb-5574

Latest Information Update: 05 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Incyte Corporation; InnoCare Pharma; Knight Therapeutics; MorphoSys; Pfizer; University Medical Center of the Johannes Gutenberg University Mainz; Xencor
  • Class Antianaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase III Marginal zone B-cell lymphoma
  • Phase II Autoimmune haemolytic anaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Haematological malignancies; Idiopathic thrombocytopenic purpura; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 23 Apr 2026 Registered for Follicular lymphoma (Adjunctive treatment, Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV)
  • 17 Mar 2026 Launched for Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) in Argentina (IV), prior to March 2026
  • 17 Mar 2026 Launched for Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) in Mexico (IV), prior to March 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top